GlassScriptPhysician profile
Melissa Short
NPI 1578617908
$2,841.86
in general payments reported to CMS, 2019-2025
28 companies · $505 in 2025
The $505 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $716 · 2022: $572 · 2023: $600 · 2024: $448 · 2025: $505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,313 · Education: $240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,313.03 |
| Education | $240.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,047.84 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $201.11 | 2021-2023 | Ultomiris, Soliris |
| Novartis Pharmaceuticals Corporation | $197.99 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $196.54 | 2021-2025 | Ajovy |
| Pfizer INC. | $161.00 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $156.53 | 2021-2022 | |
| Lilly USA, LLC | $100.33 | 2022-2024 | Emgality, Reyvow |
| Biogen, INC. | $80.80 | 2021-2022 | |
| Amgen INC. | $75.13 | 2021-2024 | Uplizna |
| Genzyme Corporation | $68.30 | 2021-2022 | |
| Averitas Pharma INC. | $48.82 | 2025 | Qutenza |
| Supernus Pharmaceuticals, INC. | $48.60 | 2021 | |
| Celgene Corporation | $47.00 | 2023 | Zeposia |
| Biohaven Pharmaceuticals, INC. | $43.78 | 2021 | |
| Allergan, INC. | $43.73 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $41.10 | 2021 | |
| Tg Therapeutics, INC. | $40.84 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $39.54 | 2022 | |
| Kyowa Kirin, INC. | $38.21 | 2023 | Nourianz |
| Mallinckrodt Hospital Products INC. | $24.33 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $23.23 | 2021 | |
| Alnylam Pharmaceuticals INC. | $22.73 | 2023 | Onpattro |
| Sunovion Pharmaceuticals INC. | $22.00 | 2021 | |
| Upsher-Smith Laboratories LLC | $16.66 | 2021 | |
| Greenwich Biosciences, INC. | $15.79 | 2021 | |
| Acorda Therapeutics, INC | $14.16 | 2021 | |
| Sk Life Science, INC. | $13.61 | 2021 | |
| Impel Pharmaceuticals INC. | $12.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Short listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.